Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2018

View Archived Issues

MenoGeniX receives grant from NIA for drug to treat menopausal hot flashes

FDA grants fast track designation for PaxVax's chikungunya VLP vaccine

GAL-200-10 controls corneal neovascularization and fibrosis in vivo

DSMB gives another recommendation for phase III FOCUS trial

Astellas reports pipeline highlights of fourth quarter of fiscal 2017

Novel oral antibiotic DDS-01 presented for treating multidrug-resistant gonorrhoea infections

Cancer therapy driven by dopamine D2 receptor antagonism shows promise

Merck & Co. patents novel LXR-beta agonists

FDA approves Tafinlar with Mekinist for BRAF-positive anaplastic thyroid cancer

Isofol receives FDA feedback on SPA for pivotal study of arfolitixorin in colorectal cancer

Sage Therapeutics identifies GluN2A and/or GluN2B NAMs

Evolve doses first pediatric patient in phase III trial of PlasmaCap IG

FDA grants priority review to Tecentriq sBLA for first-line treatment of metastatic NSCLC

Lilly initiates phase III study of mirikizumab in moderate to severe plaque psoriasis

monARC Bionetworks begins strategic integration with Roivant drug development platform

Novel ELOVL4 gene mutation tied to spinocerebellar ataxia with retinitis pigmentosa

Charles River Laboratories extends collaboration with Michael J. Fox Foundation

ORR data from KEYNOTE-407 trial of Keytruda in first-line NSCLC support sBLA submission

New mutation in SLC20A2 gene found in Fahr's disease

FDA approves IND for female hair loss trial of Histogen's HSC-660

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...